Results 111 to 120 of about 41,451 (188)

Spontaneous Tumor Lysis Syndrome Secondary to Small-Cell Neuroendocrine Carcinoma of Unknown Origin: A Rare Case Report and Literature Review

Case Reports in Oncological Medicine, 2019
Spontaneous tumor lysis syndrome (STLS), in the absence of prior chemo or radiation therapy, is rare with solid tumors. Here, we present a case of STLS secondary to a small-cell neuroendocrine tumor of unknown origin in a 66-year-old female patient who ...
Phyo Thazin Myint, Hifza Waheed Butt, Taha Alrifai, Carlos Marin   +3 more
doaj   +1 more source

Influenza A Virus (H1N1) Infection Induces Ferroptosis to Promote Developmental Injury in Fetal Tissues

Cell Proliferation, Volume 59, Issue 3, March 2026.
H1N1 infection during pregnancy specifically targets the fetal liver and lungs, triggering immune responses, tissue fibrosis and ferroptosis in parenchymal cells, ultimately leading to adverse pregnancy outcomes, offering insights into managing maternal H1N1 infections and their impact on fetal health.
Yuxi Jiang, Yao Shen, Qiongyin Zhang, Zi Liu, Yuzhen Liu, Jiaojiao Peng, Xuesong Yang, Feng Gao, Xiang‐Hong Ou, Qing‐Yuan Sun, Qiao Zhang, Guang Wang   +11 more
wiley   +1 more source

Complement System Part II: Role in Immunity [PDF]

, 2015
International audienceThe complement system has been considered for a long time as a simple lytic cascade, aimed to kill bacteria infecting the host organism.
Fremeaux-Bacchi, Veronique, Halbwachs-Mecarelli, Lise, Merle, Nicolas S., Noe, Remi, Roumenina, Lubka T.   +4 more
core   +5 more sources

Early Development of Ocadusertib, a Selective Receptor‐Interacting Serine/Threonine‐Protein Kinase 1 Inhibitor

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Receptor‐interacting serine/threonine‐protein kinase 1 (RIPK1) inhibitors are being investigated for chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib is a potent and selective allosteric inhibitor of RIPK1 and is currently being studied in clinical trials.
Simon J. Shaw, Vanessa C. Taylor, Jonathan T. Sims, Stephen Ho, Chrystelle Lamagna, Lucy Yan, Nicholas C. Reising, Andrew Chow, Eric P. Hanson, Andrew C. Vendel, Daniel J. Dairaghi, Esteban S. Masuda   +11 more
wiley   +1 more source

A Case of Spontaneous Tumor Lysis Syndrome in a Patient with Ovarian Cancer

Case Reports in Obstetrics and Gynecology, 2015
Tumor lysis syndrome (TLS) is a potentially life-threating complication of tumors or chemotherapy treatment. TLS commonly occurs in hematological malignancies, but it is very rare in patients with a solid tumor.
Kazuhiro Okamoto, Toshifumi Kinoshita, Miyuki Shimizu, Isoji Okura, Akinori Kawada, Koichi Mizobuchi, Midori Ando   +6 more
doaj   +1 more source

Fatal peripheral T-cell lymphoma presenting as hypereosinophilia and spontaneous tumor lysis syndrome: A rare case report

Indian Journal of Allergy Asthma and Immunology, 2018
Peripheral T-cell lymphomas (TCLs) are a heterogeneous group of aggressive, uncommon forms of T-cell or natural killer cell-derived non-Hodgkin's lymphomas.
Majed B Momin, Abhijeet Ingle, G Vamshi Krishna Reddy, Anamika Aluri, B Saroj Kumar Prusty   +4 more
doaj   +1 more source

New insights into the impact of neuro-inflammation in rheumatoid arthritis. [PDF]

, 2014
Rheumatoid arthritis (RA) is considered to be, in many respects, an archetypal autoimmune disease that causes activation of pro-inflammatory pathways resulting in joint and systemic inflammation.
Akasbi, Alten, Askling, Axford, Barrick, Bean, Bekkelund, Bongartz, Burmester, Burmester, Capellino, Cheng, Chiu, Chou, Combs, De Almeida, De Rycke, Detrait, Diamond, Doran, Doran, Emmer, Fayed, Feldmann, Firestein, Franklyn A. Howe, Germano, Gregersen, Gussew, Hamed, Harris, Ho, Hull, Hunter, Inan, Jacobs, Kaltsonoudis, Keane, Keystone, King, Klareskog, Lauvsnes, Lee, Leombruno, Lipsky, Listing, MacGregor, Mahdi, Malaviya, Markenson, McInnes, Medeiros, Mellor, Meseguer, Mikuls, Morris, Nadeau, Ni Mhuircheartaigh, Nicholas R. Fuggle, Nidhi Sofat, Nishioku, Norheim, O'Callaghan, Ogawa, Panayi, Parks, Rachel L. Allen, Ramiro, Rech, Rosenblum, Salliot, Salmon-Ceron, Scher, Schoels, Schweinhardt, Scott, Senaldi, Serrats, Skelly, Smolen, Sokka, Steens, Strangfeld, Symmons, Taylor, Teeling, Thomson, Tracey, Tubach, Upadhyay, van der Woude, van Heemst, van Vollenhoven, Vincent, Wallis, Wartolowska, Wegner, Wellcome Trust Case Control Consortium., Wendler, Weyand, Wolfe, Woolf, Zivadinov   +102 more
core   +2 more sources

EVALUATING THE THERAPEUTIC EFFICACY OF RESTORING WILD-TYPE P53 ACTIVITY IN P53-MUTANT TUMORS [PDF]

, 2017
The p53 transcription factor is the most frequently altered in human cancers usually via missense mutations that undermine its transcriptional activity. Clinically, TP53 mutations have been shown to be remarkably predictive of refractoriness to treatment,
Larsson, Connie A
core   +1 more source

Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis. [PDF]

, 2015
Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies.
A Kamal, AJ Novak, AP Jewell, B He, B Kuster, B Liu, BJ Schmiedel, C Berlin, C Buechele, C Buechele, C Espinosa, C Imai, C Kern, C Veuillen, CD Platsoucas, D Pende, DL Spitz, E Vivier, F Mackay, F Nimmerjahn, G Katrinakis, G Maki, GM Keating, GP Adams, HG Ljunggren, HW Ziegler, J Hilpert, K Suzuki, KS Reiners, L Bologna, M Lopez-Fraga, MK Levings, NE Kay, NE Kay, P Bruhns, P Scapini, P Schneider, R Parameswaran, S De Vita, S Herter, S Maia, S Tuyaerts, SM Jaglowski, SR Dillon, T Baessler, T Baessler, T Endo   +46 more
core   +1 more source

lHuman cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis [PDF]

, 2005
Effector-memory T cells expressing Fas (Apo-1/CD95) are switched to an apoptotic program by cross-linking with Fas-ligand (FasL). Consequently, tumors that express FasL can induce apoptosis of infiltrating Fas-positive T lymphocytes and subdue any ...
Biagi, E, Brenner, MK, Dotti, G, Pule, M, Rooney, CM, Savoldo, B, Straathof, KC, Vigouroux, S, Yvon, E   +8 more
core